scholarly journals Comparison of neo-pharmatherapy and volume building therapy in USSL

2020 ◽  
Vol 7 (1) ◽  
pp. 66
Author(s):  
Narendra B. Suratwala ◽  
Jay N. Suratwala ◽  
H. D. Jadawala
Keyword(s):  
Sudden Hearing Loss ◽  
Plasma Expander ◽  
Indian Origin ◽  
End Of Treatment ◽  
Hearing Recovery ◽  
Group A ◽  
Males And Females ◽  
Therapeutic Protocols ◽  
Group B ◽  
Series Study

<p class="abstract"><strong>Background:</strong> Objective of the study was to identify healthy individuals with idiopathic unilateral sudden hearing loss (USSL) and treating them under either of two different therapeutic protocols to judge the hearing recovery.</p><p class="abstract"><strong>Methods:</strong> Prospective crossover series study of 72 adult patients (males and females) of Indian origin was performed. Diagnosis of USSL  and treating under two different  protocols as; Group "A" was treated with oral combination form of Vinpocetine, Q-enzyme, Piracetam and B. Serrata over 3 months; while Group "B" was treated with Plasma expander IV Dextran, IV Dexamethasone, I/M Cyanocobalamine and Cyclandelate for 5 days followed by oral Dexametasone for 5 days Methycobalamine over 3 months. Common audiological and communicative parameters were applied in both treated groups to assess and analyse the responses incurred at the end of treatment. The graded system was applied to evaluate the SRT. Better outcomes based on the trialed drugs and their action is assessed.  </p><p class="abstract"><strong>Results:</strong> 61 of 72 patients successfully completed the regimes. After applying Siegel's grading for judging the SRT gains; group A had 16, 10 and 5 with grade I, II, III recovery while group B had 8, 6, 16 with grades I, II, III recovery respectively. It was noticed that group A patients showed earlier recovery of higher frequencies.</p><p class="abstract"><strong>Conclusions:</strong> Both subject groups showed improved BC gains at end treatment. There was marked hearing recovery (Gr. I, II-Siegel's classification) in group "A" was (78%) which is significant over group "B" (50%) and above natural recovery rate.</p>

A CLINICO-COMPARATIVE STUDY ON THE EFFECT OF LASHUNA SIDDHA TAILPANA POORVAK VAMANA KARMA AND NITYA VIRECHANA BY GOMUTRA HARITAKI IN THE MANAGEMENT OF HYPOTHYROIDISM

2021 ◽  
Vol 12 (4) ◽  
pp. 49-55
Author(s):  
Sheetal R Tokle
Keyword(s):  
Comparative Study ◽  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
End Of Treatment ◽  
Group A ◽  
Insignificant Difference ◽  
Randomized Control ◽  
Drug Dependent ◽  
Group B ◽  
Stimulating Hormone

Hypothyroidism is a condition in which thyroid gland doesn’t produce enough thyroid hormone. This is more prevalent among women. Management through levothyroxine is safe & may bring the value of Thyroid stimulating hormone and thyroxine to normal range but the increased dosage and continuous medication are cost expensive and make the patient into drug dependent till the end of mortal life. So, better, therapy is needed for the society through the heritage of Ayurveda especially with Shodhana therapy. Aim of Clinico-comparative study was to evaluate and compare the efficacy of Lashuna siddha Tailpana Poorvak Vamana Karma and Nityavirechana by Gomutra Haritaki in the management of Hypothyroidism. Study was conducted at Govt. Akhandanada Ayurvedic hospital, Ahmedabad, Gujarat. This study was Open labelled parallel randomized control trial. 15 patients were treated with Lashuna siddha Tailpana Poorvak Vamana Karma in group A. 15 patients was treated with Nitya Virechana by Gomutra Haritaki in group B. Washout period was 14 days. Triiodothyronine and thyroxine were compared at the end of treatment by paired t-test and Mann Whitney-U test. Lashuna siddha Tailpana Poorvak Vamana Karma was more beneficial than Nitya Virechana by Gomutra Haritaki. Insignificant difference was found on subjective and objective parameters (Weight gain, Basal metabolic rate, Serum triiodothyronine) but significance difference found on objective parameters (Thyroid stimulating hormone, Serum thyroxine).

scholarly journals Role of Rifaximin for the Treatment of Hepatic Encephalopathy in Chronic Liver Disease

2017 ◽  
Vol 7 (3) ◽  
pp. 205-211
Author(s):  
Ranjit Kumar Paul ◽  
Indrajit Kumar Datta ◽  
Habib Ahmed ◽  
Mohammad Reazul Karim ◽  
Md Nazmul Haque ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatic Encephalopathy ◽  
Hospital Stay ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Controlled Study ◽  
End Of Treatment ◽  
Group A ◽  
Group B ◽  
Ctp Score

Background: Hepatic encephalopathy (HE) is a common problem in patients with chronic liver disease (CLD) and is characterized by diminished mentation and neuromuscular abnormalities. Rifaximin has been reported to be effective for the treatment of hepatic encephalopathy (HE) in Europe and other countries. It is unknown whether rifaximin is effective for the treatment of hepatic encephalopathy in Bangladeshi patients.Methods: A prospective, randomized, single blind, placebo controlled study was conducted to evaluate the efficacy of rifaximin among patients with cirrhosis of liver with hepatic encephalopathy. A total sixty patients of HE fulfilling inclusion criteria were randomly enrolled among those admitted under Gastrointestinal, Hepatobiliary and Pancreatic Disorders (GHPD) department of BIRDEM General Hospital during August 2012 to April 2013. Patients were divided into two groups: group A (receiving Tab. rifaximin with lactulose), the total number of patients were 31(51.7%) and group B (receiving placebo with lactulose), it was 29(48.3%). Enrolled patients were followed up for 10 days or up to discharge from the hospital or death. At enrollment and at the end of treatment, gradation of HE and estimation of portosystemic encephalopathy (PSE) index was done.Results: In this study between two groups, mean age difference (p=0.404), gender difference (p=0.668) and CLD duration difference (p=0.555) were not statistically significant between two groups. At enrollment, prognostic scores e.g. Child-Turcotte-Pugh (CTP) score (p=0.489) and PSE index (p=0.934) were not significantly different between two groups. At the end of treatment, group A patients showed significantly lower HE grade (P=0.045) and PSE index (P<0.05) than group B. CTP score (p=0.552) was also lower in rifaximin treated group than placebo group but no significant difference was observed. The mean duration of hospital stay was significantly lower in group A than group B (p<0.05).Conclusions: Hepatic encephalopathy patients treated with rifaximin plus lactulose have better outcome and less hospital stay than those treated with placebo plus lactulose.Birdem Med J 2017; 7(3): 205-211

scholarly journals Role of Immediate Release and Delayed Release Omeprazole in Patients with Gastro Esophageal Reflux Disease

2017 ◽  
Vol 11 (2) ◽  
pp. 67-73
Author(s):  
Mahabub Rahman ◽  
Dewan Saifuddin Ahmed ◽  
Syeda Nur E Jannat ◽  
MM Shahin Ul Islam ◽  
Abu Ahmed Abdullah
Keyword(s):  
Reflux Disease ◽  
Immediate Release ◽  
Esophageal Reflux ◽  
Double Blind ◽  
Delayed Release ◽  
End Of Treatment ◽  
Significant Difference ◽  
Group A ◽  
Group B

Proton pump inhibitors are widely used for Gastro Esophageal Reflux Disease (GERD) treatment. This prospective double blind randomized cross over study was carried out in the Department of Gastroenterology, BSMMU from June 2007 to May 2008 to assess the efficacy of Immediate-release omeprazole (IR-OMEP) & Delayed-release Omeprazole (DR-OMEP) in relieving symptoms & healing of oesophagitis in GERD. All patients who fulfilled the inclusion criteria underwent upper gastrointestinal (UGI) endoscopy to be lebelled as nonerosive and erosive GERD. Among total 69 patients, 43 (62.3 %) had nonerosive and 26 (37.7 %) had erosive GERD. Patients were divided into group A (35) and group B (34) who received group A drugs (20 mg IR-OMEP bd) and group B drugs (20 mg DROMEP bd) from day 1-14 respectively. Then drugs were crossed over (group A: 20mg DR-OMEP bd; group B: 20 mg IR-OMEP bd) from day 15-28. Improvement of heartburn, regurgitation in each group were assessed in every week, during drug cross over and at the end and then compared between two groups. There was no significant difference in relieving heartburn and regurgitation between IR-OMEP and DR-OMEP either in erosive or nonerosive GERD (P>0.50). Patients with erosive GERD underwent UGI endoscopy at the end of treatment to see healing of esophagitis. Study showed significant healing of oesophagitis in group A after 4 weeks than group B (14%) (P<0.05) but there is no superiority of IR-OMEP over DR-OMEP in relieving symptoms of GERD.Faridpur Med. Coll. J. Jul 2016;11(2): 67-73

Effect on growth of patients with Turner's syndrome treated with low estrogen doses

1986 ◽  
Vol 113 (4_Suppl) ◽  
pp. S153-S156 ◽  
Author(s):  
MICHAEL B. RANKE ◽  
FRANK HAUG ◽  
WERNER F. BLUM ◽  
WERNER ROSENDAHL ◽  
ANDREA ATTANASIO ◽  
...  
Keyword(s):  
Bone Age ◽  
Height Velocity ◽  
Turner's Syndrome ◽  
Low Doses ◽  
Turner’S Syndrome ◽  
Control Data ◽  
End Of Treatment ◽  
Group A ◽  
One Year ◽  
Group B

ABSTRACT In 33 patients with Turner's syndrome growth during a one year period of treatment with low doses of estrogens was evaluated (group A: (N=12) PresomenR 5–9 μg/kg d; group B: (N=9) PresomenR 10–21 μg/kg d; group C: (N=12) ethinylestradiol 45–155 ng/kg d) and compared to a group (N=37) of untreated patients. The auxological evaluation was made using SDS derivations based on control data derived from 150 untreated patients. Based on chronological age (CA) SDS levels for height velocity and the increments in height at the end of treatment increased marginally. Compared to untreated patients no effect was seen when calculations were based on bone age (BA) due to an advancement in bone maturity. It is concluded that low doses of estrogens are not suitable to improve the height development in Turner's syndrome.

scholarly journals Randomized study of nutritional status and treatment toxicities of oral arginine, glutamine, and Omega-3 fatty acids during concurrent chemoradiotherapy for head and neck cancer patients

2016 ◽  
Vol 6 (3) ◽  
pp. 121 ◽  
Author(s):  
Imjai Chitapanarux
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Significant Loss ◽  
Omega 3 ◽  
End Of Treatment ◽  
Group A ◽  
Grade 3 ◽  
Group B

Background: Patients with head and neck cancer (HNC) undergoing concurrent chemoradiotherapy (CCRT) are at high risk of dysphagia, malnutrition, and immunosuppression.  Arginine, glutamine, and Omega-3 fatty acidsare immune-enhanced nutrition that can promote cellular immunity.We aimed to examine the impact of immunonutrition diet on nutritional status, and CCRT toxicities, in this group of patients.Methods: Forty patients with HNC who treated with curative CCRT were randomized to: group A (n = 20), patients who received a regular diet and dietary counselingby a protocol dietician; group B (n = 20), patients who received a regular diet plus immune-enhanced nutrition supplements and dietary counseling by the same protocol dietician. Outcome measures were weight loss, protein and energy intake, serum pre-albumin and albumin, and toxicities of CCRT were evaluated at baseline, weekly and at the end of treatment.Results:Both groups were well balanced at baseline.One patient from group A (1/20) withdrew consent.  Seven patients from group B (7/20) withdrew from the study; 1 patient could not tolerate the side effect of chemotherapy and 6 patients could not tolerate the taste of oral immune-enhanced nutrition.A significant loss in total body weight was observed in group A patients (p<0.001), whereas not significant loss in group B (p=0.109). Median percentage change from baseline of energy intake was 19.6%, and 22.9% at the end of treatment for group A, and B, respectively. The circulating levels of nutritional markers, pre-albumin and albumin decreased after CCRT in both groups. There was a significantly decreased level of albumin in group A more than group B, at the end of treatment.  During CCRT; 4 patients (20%) in group A and 1 patient(5%) in group B developed  grade 3 mucositis, respectively. One patient (5%) in group A had grade 3 radiation dermatitis. Grade 3 – 4 hematologic toxicities, mainly in absolute neutrophil count (ANC) were significant higher in group A than group B; 20% versus 0% (p=0.035).Over the 7-week period of CCRT, both intention to treat analysis and per protocol analysis revealed similar in scaled for all endpoints.Conclusions: Nutritional counseling and immuno-nutrition can reduce the deterioration of nutrition status and also significantly reduced hematologic and non-hematologic toxicity of CCRT in head and neck cancer.Keywords : immune-enhanced nutrition, concurrent chemoradiotherapy, head and neck cancer

scholarly journals OSTEOARTHRITIS;

2014 ◽  
Vol 21 (03) ◽  
pp. 471-476
Author(s):  
Malik Muhammad Yasin Awan ◽  
Ijaz Ahmad ◽  
Amer Aziz
Keyword(s):  
Case Report Form ◽  
Inclusion Criteria ◽  
Double Blind ◽  
Treatment Groups ◽  
End Of Treatment ◽  
Womac Questionnaire ◽  
Group A ◽  
Vas Scores ◽  
Group B

Objective: To assess the efficacy and safety of aceclofenac in the treatment ofosteoarthritis. Study design: Randomized double blind Phase IV trial. Place and Duration ofstudy: This study was conducted in the department of Orthopaedics & Spine Surgery, GhurkiTrust Teaching Hospital, Lahore. The duration was eight weeks. Methodology: A total of 90subjects, fulfilling the inclusion criteria and willing to give free informed consent were enrolled inthis trial. All these subjects were randomized into two treatment groups (A & B). Subjects eitherreceived Aceclofenac 100 mg twice daily or Diclofenac 75 mg twice daily for 08 weeks. During thescreening visit, information on their demographic characteristics, medical history and previousand current medications were collected. A thorough physical examination and necessarylaboratory investigations were carried out before drug administration and after the completion oftreatment (end of week 8). Clinical examination was done at baseline visit, randomization and 2, 4and 8 weeks. Gastrointestinal (GI) safety was assessed using adverse drug reaction (ADR)reports. WOMAC questionnaire was used to see improvement in activities of daily living and painwas assessed using visual analogue scale (VAS). All data was collected in the case report form(CRF). Statistical evaluation was performed at the end of the trial and results were analyzed usingSPSS. Results: 70 subjects completed the study while 20 were lost in follow-up. There were 28males and 34 females in the study with mean age of 56 years. There was a significant decrease inWOMAC and VAS scores in both groups. In group A (Diclofenac group) VAS decreased from7.107 to 2.538 (p= 0.000) and WOMAC decreased from 32.75 to 7.38 (p=0.000). In group B(Aceclofenac group), VAS decreased from 7.912 to 6.0 (p=0.001) while WOMAC decreased from37.29 to 21.50 (p=0.000) showing the efficacy of both drugs. There was also significant decreasein the disease severity in both groups at the end of treatment. But the safety profile of (Diclofenac)group A was not significant (p=0.767) as compared to (Aceclofenac) group B (p=0.022).Conclusions: Aceclofenac is efficacious and safe drug for the treatment of osteoarthritis in adultsas compared to Diclofenac.

Benign Paroxysmal Positional Vertigo Is Not a Prognostic Factor in Sudden Sensorineural Hearing Loss

2011 ◽  
Vol 146 (2) ◽  
pp. 279-282 ◽  
Author(s):  
Young Hyo Kim ◽  
Kyu-Sung Kim ◽  
Hoseok Choi ◽  
Jeong-Seok Choi ◽  
Chang Dok Han
Keyword(s):  
Pure Tone ◽  
Benign Paroxysmal Positional Vertigo ◽  
Sudden Sensorineural Hearing Loss ◽  
Pure Tone Audiogram ◽  
Lateral Canal ◽  
Positional Vertigo ◽  
Hearing Recovery ◽  
Group A ◽  
Group B ◽  
Paroxysmal Positional Vertigo

Objective. Little is known concerning the role of benign paroxysmal positional vertigo (BPPV) as a prognostic factor for sudden sensorineural hearing loss (SSNHL). The purpose of this study is to analyze the hearing recovery in patients who have SSNHL with BPPV compared with those who have SSNHL without BPPV. The study also documented the relative incidence of each semicircular canal involvement. Study Design. Case-control study. Setting. Academic tertiary otologic practice. Subjects and Methods. Ninety patients diagnosed with SSNHL with vertigo were enrolled. Clinical characteristics such as gender, age, and pure tone audiogram threshold were compared between group A (SSNHL with BPPV, n = 17) and group B (SSNHL without BPPV, n = 73). The frequency of each canal involvement was compared between group A and another 111 patients with BPPV only (group C). The proportion of patients with hearing recovery was compared between patients with or without BPPV, and between those with or without canal paresis. Results. Patients in group A did not display significant differences in the sex ratio, mean age, or initial results of pure tone audiogram threshold compared with those in group B. Most patients with SSNHL with BPPV had lateral canal canalithiasis (64.7%). The presence of BPPV had no influence on the recovery of hearing. Conclusions. The clinical characteristics of patients with SSNHL with BPPV were not different from those with SSNHL without BPPV. The lateral canal was the most frequently involved, and the presence or absence of BPPV had no dramatic impact on the outcome of SSNHL.

scholarly journals Combination of Alarm-intervention and Reboxetine in Therapy- Resistant Enuresis

2018 ◽  
Vol 37 (3) ◽  
pp. 213-219
Author(s):  
Kirill Kosilov ◽  
Irina Kuzina ◽  
Yuliya Gainullina ◽  
Vladimir Kuznetsov ◽  
Liliya Kosilova ◽  
...  
Keyword(s):  
Combined Treatment ◽  
Intervention Group ◽  
Monotherapy Group ◽  
First Line ◽  
Duration Of Treatment ◽  
End Of Treatment ◽  
Before And After ◽  
Group A ◽  
Group B

Introduction: The first-line treatments of primary monosymptomatic night enuresis (PMNE) are alarm intervention and desmopressin. Some patients are resistant to these modes of treatment. Therefore Reboxetine has been used to treat PMNE in these scenarios in recent years and published in many studies. The aim of the study was to determine effectiveness and safety of combination of Alarm intervention and Reboxetine, to treat patients with therapyresistant enuresis.Material and Methods: Two hundred and nineteen children of both sexes were participated in the experiment (average age, 11.3 years). Participants were divided into three groups: Group A (71 patients, Alarm intervention), Group B (79 patients, Reboxetine as monotherapy), Group C (69 patients, Alarm intervention + Reboxetine). The duration of treatment was twelve weeks, followed by follow-up period of twelve weeks to see efficacy.Result: There was no significant change in number of enuresis episodes per week before and after treatment in a group B. The number of enuresis episodes per a week (weekly) in a group C reached: before treatment 5.3 (1.5), after treatment 1.0 (0.8), 3 three months after the end of treatment 0.7 (0.7). The percentage of patients with PMNE in a group C was significantly less immediately after the course of treatment (17.4%), and three months after treatment (24.6%).Conclusion: Combined treatment of therapy-resistant enuresis with use of Alarm Intervention and Reboxetine gives a high percentage of cured patients both immediately after therapy (82.6%) and three months after the end (75.4%).

The outcomes of endoscopic approach for attic cholesteatoma: underwater continuous drilling versus traditional intermittent drilling

2021 ◽  
pp. 1-5
Author(s):  
D Wang ◽  
X Zhao ◽  
W Li ◽  
X Li ◽  
R Zhu ◽  
...  
Keyword(s):  
Clinical Data ◽  
Surgical Outcome ◽  
Operation Time ◽  
Endoscopic Approach ◽  
Hearing Improvement ◽  
Improvement Rate ◽  
Hearing Recovery ◽  
Operative Complications ◽  
Group A ◽  
Group B

Abstract Objective This study aimed to analyse the differences between underwater continuous drilling and traditional intermittent drilling for attic cholesteatoma. Methods The clinical data of 61 patients with attic cholesteatoma who underwent an endoscopic approach procedure were analysed. Forty patients underwent underwater continuous drilling (group A), and 21 patients underwent traditional intermittent drilling (group B). Results The operation time was 64.61 ± 12.90 minutes in group A and 79.60 ± 16.81 minutes in group B (p < 0.05). The anaesthesia time was 102.69 ± 17.93 minutes in group A and 119.82 ± 19.28 minutes in group B (p < 0.05). The dry ear time, the hearing improvement rate and the post-operative complications were no different in the two groups. Conclusion Group A and group B had no differences in surgical outcome or hearing recovery. However, treatment in the former group resulted in a significantly shortened operation and anaesthesia time.

scholarly journals Maria Adelaide brace in the management of Scheuermann’s Kyphosis

2020 ◽  
Author(s):  
Andrea Piazzolla ◽  
Davide Bizzoca ◽  
Giuseppe Solarino ◽  
Marco Brayda-Bruno ◽  
Giuseppe Tombolini ◽  
...  
Keyword(s):  
Patient Questionnaire ◽  
X Rays ◽  
Image Domain ◽  
Scheuermann’S Kyphosis ◽  
Self Image ◽  
End Of Treatment ◽  
Group A ◽  
The Mean ◽  
Group B

Abstract Purpose This prospective observational study aims to assess the MA brace effectiveness in hyperkyphosis correction, focusing also on patients’ compliance of bracing and its psychological impact. Methods Patients referring to our spine outpatient department with Scheuermann’s kyphosis (SK) from January 2011 to January 2017 were prospectively recruited. Patients were divided into two groups, according to their global thoracic kyphosis (TK): Group-A TKT0 < 60°, Group-B TKT0 ≥ 60°. The MA brace was prescribed according to SRS criteria. Full spine X-rays were analyzed at conventional times: at the beginning of treatment (T0), at 6-months follow-up (T1, in-brace X-rays), at the end of treatment (T2) and at 2-year minimum follow-up from bracing removal (T3). At T0, T2 and T3 all the patients were assessed using the Italian Version of the SRS-22 Patient Questionnaire (I-SRS22). Variability between and within-groups was assessed; a p value < 0.05 was considered significant. Results 192 adolescents (87 girls and 105 boys, mean age 13.1) were recruited. The mean global TK at recruitment was 61.9° ± 11.3°, the mean follow-up time was 57.4 months. A good patients’ reported compliance was observed: 84.9% of patients used the brace as scheduled. A mean in-brace correction (in-brace TK%) of 37.4% was observed and a mean final correction (TK%T3) of 31.6%. At final follow-up (T3), curve reduction (ΔTK ≤  − 5°) was observed in 60.4% of patients and curve stabilization (− 5° < ΔTK < 5) in 29.7% of patients. At baseline, worse SRS22-mental health (p = 0.023) and self-image mean scores (p = 0.001) were observed in Group-B, compared with Group-A. At the end of treatment (T2), an improvement of all items was observed, wit significantly better improvement of self-image domain in Group-B. Conclusion The MA brace has shown to be effective in the management of SK; good patients’ reported compliance and a positive effect on the patients’ mental status were recorded.

Sign in / Sign up

Export Citation Format

Share Document